Haemonetics
Haemonetics Corporation, commonly referred to as Haemonetics, is a leading global healthcare company headquartered in the United States. Founded in 1971, the company has established itself as a key player in the blood management industry, focusing on innovative solutions for blood collection, processing, and transfusion. With major operational regions across North America, Europe, and Asia, Haemonetics serves hospitals and blood centres worldwide. The company’s core products include blood collection systems, automated blood processing equipment, and software solutions that enhance the efficiency and safety of blood management. Haemonetics is recognised for its commitment to quality and innovation, positioning itself as a trusted partner in the healthcare sector. Notable achievements include a strong market presence and a reputation for advancing transfusion medicine, making Haemonetics a vital contributor to improving patient outcomes globally.
DitchCarbon Score
How does Haemonetics's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Haemonetics's score of 22 is higher than 54% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Haemonetics's reported carbon emissions
In 2022, Haemonetics Corporation reported total carbon emissions of approximately 25,778,620 kg CO2e, comprising 5,701,850 kg CO2e from Scope 1 and 19,361,770 kg CO2e from Scope 2 emissions. This marked a slight increase in emissions compared to 2021, where total emissions were about 25,184,440 kg CO2e, with Scope 1 emissions at 5,071,360 kg CO2e and Scope 2 emissions at 21,180,860 kg CO2e. In 2020, the company recorded total emissions of around 25,474,780 kg CO2e, with Scope 1 at 5,168,600 kg CO2e and Scope 2 at 22,983,160 kg CO2e. Haemonetics has not disclosed any Scope 3 emissions data, nor have they set specific reduction targets through initiatives such as the Science Based Targets initiative (SBTi). The company has not publicly committed to any climate pledges or reduction initiatives. As a global leader in the medical technology sector, Haemonetics is positioned to enhance its sustainability efforts, particularly in reducing its carbon footprint in line with industry standards. The absence of specific reduction targets indicates an opportunity for the company to develop a more robust climate strategy moving forward.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | |
|---|---|---|---|
| Scope 1 | 5,168,600 | 0,000,000 | 0,000,000 |
| Scope 2 | 22,983,160 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Haemonetics is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
